7月28日，SELLAS Life Sciences盘中下跌8.63%，报9.49美元/股，成交额2998.32万美元。
消息面上，思路迪医药公告其与SELLAS Life Sciences在香港国际仲裁中心的仲裁案已获最终裁决，SELLAS提出的所有仲裁主张被全面驳回，且SELLAS须承担对方仲裁相关开支合计798.3万港元，需于8月7日前缴付。与此同时，思路迪医药宣布将继续推进Galinpepimut-S在大中华区的开发与商业化工作。仲裁败诉意味着SELLAS在该区域合作中的争议主张未获支持，同时面临额外费用支出，对市场情绪形成压制。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.